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The Comprehensive Sickle Cell Center (CSCC) at the 
Children’s Hospital of Philadelphia (CHOP) provides routine 
and acute care for approximately 1000 patients with sickle cell 
disease (SCD). One hundred twenty patients with SCD are 
currently managed with chronic transfusion therapy, either 
by simple transfusion or by erythrocytapheresis to maintain a 
percent hemoglobin S (HbS) level of less than 30 or 50 percent, 
depending on the indication. The most common indication 
for chronic transfusion therapy at our institution is stroke 
prevention, either primary or secondary, followed by recurrent 
acute chest syndrome and splenic sequestration, and, less 
commonly, chronic cardiac disease or severe recurrent vaso-
occlusive episodes. Many children receive acute or episodic red 
blood cell (RBC) transfusions when admitted to the hospital for 
parvovirus-associated aplastic crisis, acute chest syndrome, 
splenic sequestration, stroke, and transient ischemic attacks, 
or as preoperative therapy to decrease the risk of acute chest 
syndrome after general anesthesia.
Although transfusion therapy remains a mainstay for 
the treatment of acute and chronic complications of SCD, the 
risk of alloimmunization to minor RBC antigens continues to 
be a significant complication.1–5 Alloimmunization can have 
severe clinical consequences, not only because it can lead 
to significant delays in providing compatible blood, but also 
because alloimmunization in patients with SCD is associated 
with delayed hemolytic transfusion reactions (DHTR), 
autoantibody formation, and hyperhemolysis (reviewed 
in Wahl and Quirolo6). At CHOP, we have implemented 
specialized transfusion protocols for patients with SCD to help 
decrease alloimmunization risk.
Transfusion Protocol
More than two thirds of alloantibodies formed by patients 
with SCD have Rh blood group (D, E, e, C, c) specificities, and 
the three most common alloantibodies in patients with SCD 
are directed against C, E, and K.4,7 Despite efforts to address 
this problem by prophylactic matching for C, E, and K  (in 
addition to routine matching for ABO and D), about 10 percent 
of transfused patients with SCD still become alloimmunized.3,5 
Our current practice for transfusion of patients with SCD 
is to match prospectively for C, E, and K, and to provide 
ethnically matched RBC units when possible. An extended 
RBC phenotype is performed on samples from all patients 
with SCD using an untransfused specimen, typically within 
the first year of life or at the first outpatient visit if transferring 
care from another institution. We determine ABO, D, C, c, E, 
e, K, Fya, Fyb, Jka, Jkb, M, N, S, s, Lea, Leb, and P1 status by 
serologic methods. If a patient has been recently transfused, 
DNA-based methods are used to determine the predicted RBC 
phenotype. The extended phenotype is often helpful in guiding 
the serologic workup of new RBC antibody findings, as well 
as in prospective matching for additional minor antigens. 
For patients who have developed multiple alloantibodies or 
have a history of hyperhemolysis syndrome, we prospectively 
match RBC units for additional antigens, typically in the 
Kidd, Duffy, and MNS systems. This extended phenotype 
matching is performed on an individual case basis, taking into 
consideration the alloantibodies already formed, the antigens 
still at risk for antibody development, and the feasibility of the 
resulting extended match request.
Antibodies to low-incidence RBC antigens are also 
observed in our chronically transfused patients. Although 
these antigens are considered low-incidence because they 
occur in less than 1 percent of the general donor population, 
some are found at much higher incidence among African 
American donors.8 In many cases, reagents to screen RBC 
units for these antigens are not readily available. The blood 
supplier may be able to provide units from donors known 
historically to be antigen negative even if current donations 
cannot be screened. Two additional strategies are used to 
screen units for transfusion to patients with antibodies to low-
incidence antigens. If the specificity is demonstrable in the 
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current serum sample based on reactivity with cells known to 
express the low-incidence antigen, then a negative anti-human 
globulin (AHG) phase crossmatch is accepted as an adequate 
screen for antigen-negative donor units. If the specificity is not 
demonstrable in the current serum sample, we may be able 
to use confirmed antibody-positive serum samples from the 
same patient that have been retained in frozen aliquots for 
this purpose. If none of these measures is available to screen 
for low-incidence antigens, RBC units must be issued with 
an unscreened status, for which our policy requires clinician 
acknowledgment by signature on a protocol waiver.
Matched blood for patients with SCD is most likely to be 
found among African American donors, whose RBCs more 
commonly lack C, E, K, S, Fya, Fyb, and Jkb compared with 
Caucasian donors.9 In 1997, CHOP, the Penn-Jersey American 
Red Cross (ARC), and the local chapter of the Sickle Cell Disease 
Association of America initiated the Blue-Tag Program to direct 
blood from African American donors to children with SCD.10 
Blood donors voluntarily self-identify as African American and 
agree to have their blood specifically support children with SCD 
by attaching a special blue tag to their donation. With 1200 to 
1600 RBC units collected per month, these donors support the 
majority of transfusions for patients with SCD at CHOP and 
St. Christopher’s Hospital for Children. The primary reason a 
patient with SCD may not receive program units is the presence 
of alloantibodies that preclude an appropriate match from the 
Blue-Tag RBC inventory.
The issue of RBC alloimmunization within the Rh blood 
group system is greatly complicated by the genetic diversity 
of this locus within populations of African origin and the 
limitation of current serologic reagents to distinguish the many 
variant antigens. Altered D, C, and e often underlie complex Rh 
alloimmunization in patients with SCD. Many of these cases 
appear as apparent autoantibodies with relative specificities 
in the Rh system; however, molecular analysis reveals that 
many of these antibodies represent alloantibodies in the Rh 
system for which serologic reagents are not available. RH 
genetic testing can now be used in the clinical setting to detect 
altered RHD and RHCE in individuals at risk for producing 
antibodies to high-incidence Rh antigens.11 We use genotyping 
to resolve complex Rh antibodies, particularly for those 
patients who develop antibodies in the face of conventional 
antigen matching. Additionally, we obtain an RH genotype 
to supplement the RBC antigen profile for all chronically 
transfused patients with SCD.
One common variant RH allele in African Americans is 
the hybrid RHD-CE-D, which results from RHCE exons 3 
through 7 replacing the region of RHD encoding D epitopes.12 
The RBCs with this hybrid protein type as D– and C+, but 
patients often develop anti-C when exposed to C+ RBCs, 
and this can be associated with a DHTR. In our blood bank, 
patients with the hybrid RHD-CE-D who lack an RHCE allele 
encoding conventional C receive C–  RBCs to prospectively 
prevent anti-C production, consistent with the general policy 
for prophylactic C matching. Additional RBC matching for 
Rh variants is not performed because the clinical relevance of 
most variant alleles is unknown.13 Future studies to determine 
which additional variants should be included in prospective 
matching to prevent alloimmunization and hemolytic 
transfusion reactions is paramount, as molecular testing could 
provide superior outcomes.
Donor RBC Selection Protocols
In addition to performing prospective C, E, and K antigen 
matching and providing ethnically matched RBCs when 
possible, we provide patients with SCD HbS-negative units 
that are screened by the blood bank via a rapid solubility 
test. Because the survival of transfused RBCs declines with 
storage, we provide RBC units collected within 21 days 
for patients on chronic transfusion programs. The goal is 
to improve RBC survival, maintain the desired HbS level 
between transfusion visits, and achieve longer transfusion 
intervals with concomitantly decreased iron burden. For 
episodic or acute transfusion of patients with SCD, we do not 
have a restriction on the age of the RBC units issued. The 
CHOP blood bank provides prestorage leukocyte-reduced 
cytomegalovirus (CMV)-safe blood to all patients, including 
those with SCD. Irradiation is performed on-site, just before 
issuance for transfusion, and is applied to the great majority 
of transfusions using protocols based on patient location and 
service. One exception is RBC units ordered on-call for the 
operating room for potential bleeding, in which the units are 
not irradiated unless medically indicated for the patient. In 
the case of SCD, on-call units would be irradiated. Many of 
our patients with SCD, particularly those who are chronically 
transfused, require washed RBC components owing to 
recurrent allergic or cytokine-mediated transfusion reactions 
despite premedications. RBC washing is performed on-site 
and within 24 hours of transfusion.
Emergency Protocols
If emergent transfusion is necessary, the blood bank will 
issue uncrossmatched O– units or uncrossmatched type-
specific blood (based on historical ABO type on at least two 
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prior specimens performed by the CHOP blood bank). Both 
protocols require a waiver signed by the treating physician. 
In addition, if time allows, C-, E-, and K-matched or antigen-
negative uncrossmatched units can be requested by the 
medical team. Because we transfuse a large number of patients 
with SCD on a chronic basis, units known to be negative for 
C, E, and K are usually on the shelf and readily available for 
emergency transfusion. At CHOP, the emergency department 
and intensive care units have satellite blood component 
refrigerators that store O– RBC units that are unscreened 
for C, E, and K. These components have occasionally been 
used for patients with SCD who have life-threatening anemia 
requiring emergent transfusion. When uncrossmatched blood 
is transfused, whether issued by the blood bank or from 
the satellite blood component refrigerators, a retrospective 
crossmatch is performed with the patient’s specimen and a 
segment of the RBC unit that is retained in the blood bank. For 
patients with SCD, we would also retrospectively phenotype 
unscreened RBC units for their C, E, and K status to provide 
exposure information to the medical team.
Warm Autoantibodies in Patients With SCD
It has been our experience that many patients with SCD 
who are chronically transfused form warm autoantibodies 
detectable for various lengths of time in the antibody screen. 
If a patient demonstrates a warm autoantibody in the serum, 
a sample is usually sent to our reference laboratory for 
allo- or auto-adsorption studies to evaluate for underlying 
alloantibodies. For chronically transfused patients, we 
typically arrange for blood samples to be drawn 2 to 3 days 
before a scheduled transfusion so that these adsorption studies 
can be performed in advance. In part because of proximity, our 
reference laboratory can also perform these studies within 6 
hours for emergent situations. After the adsorption studies are 
completed, we request RBC units from our blood supplier that 
are matched for C, E, K, and any other antigens against which 
the patient has a past or current history of alloimmunization; 
crossmatches are performed in our blood bank, and the least 
incompatible units are issued for transfusion. Currently, 
we use the gel method for routine antibody screening and 
crossmatching. If a warm autoantibody is a repetitive finding 
for a chronically transfused patient, our blood bank may repeat 
the antibody screen using a low-ionic strength saline tube 
method, and if the warm autoantibody is not detectable by 
tube method, we often elect to perform subsequent antibody 
screens and crossmatches for that particular patient using the 
tube method.
Protocol Outcomes and Future Directions
More than 5000 RBC units are transfused each year at 
CHOP to patients with SCD, which constitutes more than 40 
percent of all RBC units issued by our blood bank. Selecting 
and providing the appropriate RBC units requires tremendous 
coordination between the CHOP blood bank, hematology 
service, apheresis team, and the Penn-Jersey ARC, which 
supplies the blood components. The risk of alloimmunization 
and DHTRs for patients with SCD has been significantly 
minimized by prospective partial phenotype matching in 
the Rh and Kell blood group systems. Additionally, the Blue-
Tag African American blood donor recruitment program in 
Philadelphia has increased the local supply of ethnically similar 
RBCs whose blood group antigen profiles more closely match 
the patients’. From a cost perspective, 4.7 percent of RBC units 
issued to patients with SCD were matched for a single antigen, 
33 percent were matched for two antigens, and 61 percent 
were matched for three antigens, with the remaining matched 
for more than three antigens. This antigen matching increased 
the blood acquisition cost for the program by 65 percent over 
the base cost of RBC units. In addition, a handling fee for the 
Blue-Tag donor program added 3 percent to the overall cost for 
the program.
Most recently, RH genotyping of patients has improved our 
understanding of Rh antibody production in SCD and offers 
the possibility of eliminating further Rh alloimmunization if 
partnered with genotyping of donors. Commercial polymerase 
chain reaction–based technology is now available to detect the 
majority of RH variants, allowing high-throughput genotyping 
of donors and patients to select more accurately matched 
RBCs. Our goal is to characterize RH in all patients with 
SCD, to identify those who would benefit from RH genetically 
matched transfusions, and to improve transfusion outcomes 
by applying molecular methods in transfusion medicine.
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